Navigation Links
CEL-SCI Signs Definitive Agreement to Raise $5 Million in Registered Direct Offering
Date:6/24/2009

VIENNA, Va., June 24 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM), a late stage cancer immunotherapy company, today announced that it has entered into a definitive agreement with one institutional investor to sell 12.5 million units, with each unit consisting of one of the Company's common shares and 0.67 warrants to purchase one share of common stock, for gross proceeds of approximately $5.0 million, before deducting placement agent fees and estimated offering expenses, in a "registered direct" offering. The investor has agreed to purchase the units at a purchase price of $0.40 per unit. The warrants, which represent the right to acquire an aggregate of up to 8.375 million common shares, will be exercisable at any time on or after 181 days from the Closing Date and prior to the 5-year anniversary at an exercise price of $0.50 per share, which was above the closing price of the Company's common shares on the NYSE AMEX Market on June 23, 2009. Chardan Capital Markets, LLC acted as placement agent for the offering.

The transaction is expected to close on or about June 29, 2009, subject to satisfaction of customary closing conditions.

Geert Kersten, Chief Executive Officer of CEL-SCI, said: "We are planning to use this money to achieve a number of major milestones, key among them are the acceleration of our H1N1 swine flu work and the validation of our manufacturing facility for contract manufacturing services and to produce our cancer drug Multikine for the planned Phase III clinical trial."

The securities described above are being offered by CEL-SCI Corporation pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission.

This press release shall not constitute an offer to sell or the solicitation of an offe
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. CEL-SCI to Present at the Noble Financial Conference
2. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
3. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
4. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
5. CEL-SCI Takes Delivery of New Manufacturing Facility
6. Updated Pictures of CEL-SCI Manufacturing Facility Available Online
7. CEL-SCI Corporation Releases Letter to Shareholders
8. CEL-SCI Corporation Announces 2008 Financial Results
9. CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products
10. CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease
11. CEL-SCIs L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Grace Century portfolio project, Provia Laboratories , ... the Board, to the National Stem Cell Ethics Committee ... by the Ministry of Health on behalf of the Government ... More than a year after Bahamian Parliament passed the ... Christie said the government has completed the accompanying regulations and ...
(Date:10/30/2014)... the key challenges in the development of quantum technologies ... In a paper published today (28 October) in ... how to make a new type of flexibly designed ... as high-precision sensors and specialised superfast computers, often depend ... methods for trapping these tiny particles are hugely problematic ...
(Date:10/27/2014)... 2014 The Italian company ... and sell its artificial "lower limb", after the ...      (Photo: http://photos.prnewswire.com/prnh/20141027/713097 ) ... the definitive judgement has arrived: Roadrunnerfoot, the small ... accessible hi-tech prostheses with composite materials, has won ...
(Date:10/27/2014)... October 27, 2014 New Q4-2014 ... SoundConnect , an industry leading unified communication and ... and agents to deliver cloud-based audio and web/video ... opportunities. , With SoundConnect’s Q4 incentive partners ... video and/or web conferencing licenses sold, now through ...
Breaking Biology Technology:Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 3Italian Lower Limb Prosthesis Company Wins Lawsuit Against German Giant Ottobock 2SoundConnect Unveils Q4 Partner Incentives 2
... computational tools and a state-of-the-art scanning transmission electron ... Iowa State University materials science and engineering researchers ... solid metallic materials known as metallic glasses. ... Review Letters , the findings fill a gap ...
... Richard Dolinar, chairman of the Alliance for Safe Biologic ... U.S. Food and Drug Administration (FDA) should resolve before ... in prepared testimony for the FDA,s May 11th public ... for the development of biosimilar products. ...
... May 10, 2012 Aviir Diagnostic Laboratory has entered ... as a participating provider with Stratose Network and their ... Stratose A true pioneer of claims ... PlanCare America, 4MOST Health, Qualident and KeyClaims) works to ...
Cached Biology Technology:In metallic glasses, researchers find a few new atomic structures 2In metallic glasses, researchers find a few new atomic structures 3Alliance for Safe Biologic Medicines Chairman Urges FDA to Ensure that Patient Safety is the Cornerstone of Biosimilar Pathway 2Aviir Laboratories Announce National Agreement with Stratose 2Aviir Laboratories Announce National Agreement with Stratose 3
(Date:10/29/2014)... 29, 2014, Beaverton, OR) New research presented ... International Conference in Houston, TX showed for the ... HPV infection in women using a readily available ... study, presented by Dr. Judith A. Smith, Pharm.D., ... and Reproductive Sciences at The University of Texas ...
(Date:10/29/2014)... is all the rage. Thousands of scientists worldwide are ... whether titanium dioxide nanoparticles from sun creams can get ... nanotubes from electronic products are as hazardous for the ... in food can get into the blood via the ... funds are flowing – and the number of scientific ...
(Date:10/29/2014)... the Barcode of Life Data Systems (BOLD). ... Data Journal (BDJ) used specimen records downloaded ... a human-readable text developed in manuscript within the ... study the species distributions of ten Nearctic species of ... originally designed to support the generation and application of ...
Breaking Biology News(10 mins):HPV infections in women eradicated by AHCC, Japanese mushroom extract 2Nanosafety research: The quest for the gold standard 2Nanosafety research: The quest for the gold standard 3Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2
... throwing unwanted fish overboard from commercial boats could put one ... say researchers at the University of Leeds. , New research ... which gannets rely on unwanted fish and offal thrown from ... "The North Sea has undergone massive environmental changes over the ...
... Scientists at the Lombardi Comprehensive Cancer Center at Georgetown University ... to tease apart in the most comprehensive way ever ... cells in cancer development and treatment. This protein determines which ... and how she will fare during her treatment. The researchers, ...
... NEW YORK, March 22, 2010 The Juvenile ... for diabetes research worldwide, said today that it will ... Organization, and The Hebrew University of Jerusalem on drugs ... type 1 diabetes. The program, under the ...
Cached Biology News:Fishing discard ban could damage sea bird success, scientists warn 2Lombardi receives $7.5 million grant for Breast Cancer Center for Cancer Systems Biology 2Lombardi receives $7.5 million grant for Breast Cancer Center for Cancer Systems Biology 3JDRF, Pfizer, Hadassah Medical and the Hebrew University announce collaboration 2
... traps a wide variety of solvent vapors that can ... flask (GCF400) allows for the collection of liquid into ... time minimizes waiting period., Ultra low -104 ... , Digital Display of ...
... RCT series of refrigerated cold traps offers ... of low volatility/aqueous solvents or high volatility ... other vacuum concentrators/centrifugal evaporators. Also used for ... such as used in electron microscopes. Can ...
... Trap is specifically designed for efficient ... as DMSO and DMF in the ... refrigeration system set at -5 o ... DMSO, while completely eliminating the risk ...
96 Well Plate Sterile, RE bottom; consistent medium binding affinity for hydrophobic complexes and proteins....
Biology Products: